Vivet Therapeutics
Latest round
- Series A
Last raised
- Apr 2017
Total raised
- $29M
Investors
- 7
About Vivet Therapeutics
Founded in 2016 and based in Paris, France, Vivet Therapeutics SAS operates as a developer of gene therapy treatments for orphan diseases. The company was founded by its CEO, Jean-Philippe Combal, and CSO, Gloria Gonzalez-Aseguinolaza. Vivet Therapeutics develops gene therapies and orphan drugs for rare inherited metabolic disorders. The firm’s gene therapy product, VTX-806, is an (adeno-associated virus) AAV-based gene therapy for cerebrotendinous xanthomatosis (CTX).
Who invested in Vivet Therapeutics
7 investors across 1 round
See all investors in Vivet Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Apr 1, 2017
Amount
$29M
Investors
Questions about Vivet Therapeutics
Who invested in Vivet Therapeutics?
Vivet Therapeutics has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Vivet Therapeutics raised?
Vivet Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Vivet Therapeutics last raise money?
Vivet Therapeutics's most recent round on record is a Series A, in Apr 2017.
What does Vivet Therapeutics do?
Founded in 2016 and based in Paris, France, Vivet Therapeutics SAS operates as a developer of gene therapy treatments for orphan diseases.
Where is Vivet Therapeutics headquartered?
Vivet Therapeutics is headquartered in Paris, France.
Which VCs invest in companies like Vivet Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Vivet Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Vivet Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.